TY - JOUR
T1 - Post-stroke complications
T2 - Epidemiology and prospects for pharmacological intervention during rehabilitation
AU - Meschia, James F.
AU - Bruno, Askiel
PY - 1998
Y1 - 1998
N2 - Stroke can be associated with a number of sequelae which require treatment during rehabilitation of the patient. These include aphasia, depression and emotionalism, central pain, spasticity and urinary incontinence. Patients will also require rehabilitation to optimise motor recovery. At present, no reliable evidence favours any drug for the treatment of aphasia or post-stroke urinary incontinence. On the basis of small, unconfirmed. randomised trials, a tentative recommendation can be made for the use of the antidepressants nortriptyline, citalopram, maprotiline or fluoxetine in post-stroke depression. and nortriptyline or citalopram in post-stroke emotionalism. The tricyclic antidepressant amitriptyline appears to be useful for the control of central post-stroke pain, and botulinum toxin A should be considered for post-stroke spasticity. Although limited data suggest that amphetamine and dexamphetamine can enhance motor recovery, these drugs remain investigational and their use cannot be recommended outside of clinical trials.
AB - Stroke can be associated with a number of sequelae which require treatment during rehabilitation of the patient. These include aphasia, depression and emotionalism, central pain, spasticity and urinary incontinence. Patients will also require rehabilitation to optimise motor recovery. At present, no reliable evidence favours any drug for the treatment of aphasia or post-stroke urinary incontinence. On the basis of small, unconfirmed. randomised trials, a tentative recommendation can be made for the use of the antidepressants nortriptyline, citalopram, maprotiline or fluoxetine in post-stroke depression. and nortriptyline or citalopram in post-stroke emotionalism. The tricyclic antidepressant amitriptyline appears to be useful for the control of central post-stroke pain, and botulinum toxin A should be considered for post-stroke spasticity. Although limited data suggest that amphetamine and dexamphetamine can enhance motor recovery, these drugs remain investigational and their use cannot be recommended outside of clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=0031748809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031748809&partnerID=8YFLogxK
U2 - 10.2165/00023210-199809050-00003
DO - 10.2165/00023210-199809050-00003
M3 - Review article
AN - SCOPUS:0031748809
SN - 1172-7047
VL - 9
SP - 357
EP - 370
JO - CNS Drugs
JF - CNS Drugs
IS - 5
ER -